Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 8/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 8/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 8/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 8/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 5/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19374743 | 0.89 | MAPT (0.34) | ALDH1A1MAPTAPOBEC3AAPOBEC3GNFKB1 | |
| SCHEMBL34473101 | 0.77 | GABRG2 (0.40) | ALDH1A1GABRG2GABRB3GABRA5GABRA2 | |
| SCHEMBL34472920 | 0.76 | GABRG2 (0.39) | ALDH1A1GABRG2GABRB3GABRA5GABRA2 | |
| SCHEMBL4735920 | 0.74 | CYP3A4 (0.41) | ALDH1A1MAPTSYKMEN1CYP1A2 | |
| SCHEMBL34472556 | 0.74 | GABRG2 (0.38) | ALDH1A1GABRG2GABRB3GABRA5GABRA2 | |
| SCHEMBL34474024 | 0.73 | GABRG2 (0.38) | ALDH1A1MAPTGABRG2GABRB3GABRA5 | |
| SCHEMBL34473068 | 0.73 | GABRG2 (0.38) | ALDH1A1MAPTGABRG2GABRB3GABRA5 | |
| SCHEMBL34472621 | 0.73 | GABRG2 (0.37) | ALDH1A1MAPTGABRG2GABRB3GABRA5 | |
| SCHEMBL34472710 | 0.73 | GABRG2 (0.37) | ALDH1A1MAPTGABRG2GABRB3GABRA5 | |
| SCHEMBL29624993 | 0.73 | SYK (0.34) | ALDH1A1NFKB1NFKB2RELASYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794600-B1 | 2,3-Dihydro-benzo[1,4]oxazine derivatives and related compounds as phosphoinositide-3 kinase (PI3K) inhibitors for the treatment of e.g. rheumatoid arthritis | NOVARTIS AG (CH) | 2017-12-06 | — | — | EP | disclosed |
| EP-2794600-B1 | 2,3-Dihydro-benzo[1,4]oxazine derivatives and related compounds as phosphoinositide-3 kinase (PI3K) inhibitors for the treatment of e.g. rheumatoid arthritis | NOVARTIS AG (CH) | 2017-12-06 | — | — | EP | disclosed |
| US-9763952-B2 | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-9763952-B2 | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-9763952-B2 | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-9539260-B2 | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | NOVARTIS AG (CH) | 2017-01-10 | — | — | US | disclosed |
| US-9539260-B2 | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | NOVARTIS AG (CH) | 2017-01-10 | — | — | US | disclosed |
| US-9539260-B2 | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | NOVARTIS AG (CH) | 2017-01-10 | — | — | US | disclosed |
| US-20160106753-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| US-20160106753-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| US-20160106753-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| EP-2794600-A1 | DIHYDRO-BENZO-OXAZINE AND DIHYDRO-PYRIDO-OXAZINE DERIVATIVES | Novartis AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013093849-A1 | DIHYDRO-BENZO-OXAZINE AND DIHYDRO-PYRIDO-OXAZINE DERIVATIVES | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013093849-A1 | DIHYDRO-BENZO-OXAZINE AND DIHYDRO-PYRIDO-OXAZINE DERIVATIVES | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| US-20130165436-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | NOVARTIS AG (CH) | 2013-06-27 | — | — | US | disclosed |
| US-20130165436-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | NOVARTIS AG (CH) | 2013-06-27 | — | — | US | disclosed |
| US-20130165436-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | NOVARTIS AG (CH) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165436-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | PDXK, PDK1, DPYD | ALDH1A1 692/4885MAPT 1546/4885APOBEC3A 4684/4885 |
| US-20160106753-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | PDXK, PDK1, DPYD | ALDH1A1 692/4885MAPT 1546/4885APOBEC3A 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.